Key Takeaways
- Revenue shift landed, margins lagged: Revenue moved in line with expectations as Q1 spillover materialized, but a lower-margin business mix kept the gross margin improvement muted despite better fixed-cost absorption.
- Order backlog fell sharply: Backlog dropped ₹147.7 crore QoQ, driven by lumpy consumption of one large defense order; management expects recovery as that order concludes and new wins fill in.
- Altek acquisition reshapes the portfolio: The Connecticut-based EMS player brings medical and industrial diversification, a US manufacturing footprint, and a similar low-volume, high-mix DNA.
- Double-digit EBITDA margin still the line: Management deflected formal guidance but committed to ending FY25 with a double-digit margin, with H2 carrying the load after a softer H1.
- What to watch next quarter: Whether the order book begins recovering as promised, the pace of working capital improvement toward the 90-100 day target, and any clarity on the Middle East supply-chain disruption.
Revenue & Profitability
- Q1-to-Q2 shift materialized: Deliverables that slipped from Q1 landed in Q2, bringing revenue in line with the plan flagged last quarter.
- Volume improved, mix offset the gain: Higher volumes drove better fixed-cost absorption at the EBITDA level, but gross margin was slightly lower because of a different business mix, so the QoQ step-up was smaller than hoped.
- Large low-margin order concluding: One large contract carrying lower margins is winding down; as it exits, the rest of the business, which carries healthier margins, is expected to drive appreciable margin improvement next year.
- SG&A absorption to help: Management stated it will not add SG&A linearly with growth going forward, so operating leverage should kick in as the top line scales.
- H1/H2 seasonality holds: H1 is typically lower than H2 in both revenue and EBITDA, and the current year is following the same trajectory; EBITDA percentage is lower in H1.
- PAT gap explained by finance costs: The gap between EBITDA and PAT is largely due to higher finance costs because free cash flow was negative in H1, requiring borrowing; the plan is to liquidate in H2 as cash flow turns positive.
- One-time costs pushed to Q3: No one-time transaction costs hit Q2; all such costs will be taken in Q3 and called out separately.
Anthony Montalbano: "I think you'll find that EBITDA margins, 9%-10% is relatively healthy in the Indian EMS sector. And then, it's definitely extremely healthy on the global sector as well where, EBITDA margins are anywhere from 3%, 4%, 5%, sometimes 6%."
Order Book & Demand Environment
- Backlog declined on lumpy consumption: Order backlog fell ₹147.7 crore QoQ because one large defense order is being consumed very fast; management expects backlog to start recovering as that order concludes.
- Order book needs to improve: Management acknowledged the order book definitely needs to improve to drive growth, and stated it expects to see traction and improvement in H2, with some positive trends already visible.
- Industrial segment still digesting inventory: Key industrial clients built up inventory that is still being consumed; recovery in the order book from that sector is expected but will take 1-2 more quarters.
- New industrial logo ramping fast: A new client in the industrial sector, announced last quarter, operates in a segment that moves extremely fast; its revenue potential for next fiscal year alone is considerable and could make it a top 3-4 client next year and possibly top 1-2 the following year.
- Defense creates lumpiness: When the current large defense order concludes, there will be a time gap before the next order, creating lumpiness in the order book; the QRSAM missile opportunity has long timelines from program announcement to execution, with details still unavailable.
- Middle East disruption is supply-side: The conflict is causing shipment delays both inward and outward and parts availability issues; cost is not a big factor as vendors honor PO terms, but delays and scheduling are the main headaches and the situation remains unpredictable.
- Two new logos added: A defense contract in India and a global oil services company were added in Q2.
Anthony Montalbano: "We did announce a new logo, a new client in an industrial sector last quarter. And this sector actually moves extremely fast with the segment this client is in. So, we see that just the revenue potential from this new logo alone for our next fiscal year to be quite considerable to the fact where it would probably be a top three or four clients for us alone in the next fiscal year."
Working Capital & Balance Sheet
- DIO improved sharply: Days inventory outstanding fell from 184 to 122 days; the 184-day figure was partly inflated by lower Q1 revenue; the internal goal is 90-100 days on a sustainable basis, with an action plan in place.
- DSO also moved down: Days sales outstanding decreased from 92 to 82 days, with further scope for improvement as the business scales.
- Job half done: Management characterized the working capital improvement as fair but "job half done," with continued improvement targeted in coming quarters.
- Customer advances declining: Newer orders are not coming with customer advances, so advances are declining; this will reflect in inventory as well.
- Israel adds ~20 days to working capital: The Israel operation contributes about 20 days to the overall working capital number.
- Debt to decline organically: Debt levels will go down as positive cash is generated; debt taken for M&A is long-term and returns from that asset will more than surpass the cost to service it; the reduction comment applies to the organic business perspective.
- IPO proceeds fully utilized next quarter: Inorganic spend through acquisitions and general corporate purposes were shown as unutilized as of September 30; next quarter will show them fully utilized.
Altek Electronics Acquisition
- What Altek brings: Based in Connecticut, operating since the early 1970s, Altek provides high-value electronics manufacturing services focused primarily on medical and industrial segments, with defense also a fit; it has 80,000 sq ft of manufacturing, over 200 employees, room to expand on the existing site, and healthy financial metrics.
- Strategic logic: The acquisition balances the portfolio (95% industrial and medical) against Cyient DLM's growing aerospace and defense concentration; the Connecticut location is attractive for the types of clients and industries served, including medical.
- Business model fit: Altek operates a low-volume, high-mix model similar to Cyient DLM, and brings engineering support to products, working with clients on additional manufacturing and engineering to get products going.
- Integration timeline: Starting next quarter, Altek will be integrated into overall updates.
- Purchase price allocation pending: Goodwill and amortization impact are not yet determined; there are considerable assets coming with the acquisition, so intangibles will be less than for a services company.
Anthony Montalbano: "For us, the value proposition needs to include having a similar type of DNA in the business where our clients who do business with us today in India would feel very confident having their type of business being supported in a similar type of operation in other geographies."
Revenue Mix & Segments
- Domestic mix spiked on one defense order: The domestic share was very high this quarter largely because one defense order was executed at a faster pace; this is not the norm and the mix is expected to return to about 70% export and 30% domestic as things stabilize.
- The 70-30 target includes Altek: The 70-30 export-domestic comment takes into account the inorganic mix, which will all be counted as exports.
- Aerospace and defense growth impressive: The segment grew to become a large piece of the pie this quarter.
- Industrial weakness persists: Inventory built up at key industrial clients is still being consumed; order book recovery from that sector is expected in 1-2 more quarters.
- EV space in focus for India: Management flagged the EV space as an area of interest and focus in the India market, adding to the four segments already in; more details will be shared as pipeline updates come.
- Future mix could shift again: Going forward, the mix might be more export-focused, but could shift again if Indian business in new areas grows.
Strategy & Growth Levers
- Core business remains the growth engine: Growth will still come from the core business, with focus on larger contracts with key clients, Indian defense where the pipeline is increasing, and the build-to-spec offering starting to drive a shift, especially in the coming fiscal year.
- 30% organic CAGR target intact: The multiyear 30% CAGR outlook is still the target; it is organic and does not include inorganic contributions; with Altek, the combined business should maintain that growth level from both top and bottom line.
- Further acquisitions on the radar: Management will continue to pursue additions aligned with similar priorities: capability, geography, clients, proximity to clients, and additional capabilities that align with growth.
- Parent semiconductor synergy is years away: There is a continuum from chip design to board and box build, and therefore synergy with the parent's semiconductor business, but nothing is expected to play out from that for at least a few years.
- Head of Sales resigned: Joseph Crowley, Head of Sales, resigned due to a medical situation; the position was vacated due to the timeframes involved.
Krishna Bodanapu: "I think there is a synergy because the continuum is really first you build it - first you design, then you build the chip and then you build the board and the box and everything around it. So, in that sense there is a continuum, I will say and therefore there is a synergy, but I think we won't expect anything to play out from that synergy at least for a few years because we will first have to start designing the chips and then looking at how those chips can be consumed in science DLM."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year EBITDA margin | Flat YoY, comparable with FY24; H2 will be better than H1 | FY25 |
| Double-digit EBITDA margin | "We will definitely end the year with double-digit" | FY25 exit |
| PAT trajectory | Improved trajectory in H2 as revenue and EBITDA peak | H2 FY25 |
| DIO target | 90-100 days on a sustainable basis | No fixed date (action plan in place) |
| Working capital | Continued improvement in coming quarters | Coming quarters |
| IPO proceeds | Fully utilized (inorganic + general corporate purposes) | Next quarter (Q3 FY25) |
| Industrial order book recovery | Recovery expected as client inventory is consumed | 1-2 more quarters |
| 30% organic CAGR | Still the target; does not include inorganic | Multiyear |
| Altek integration into reporting | Integrated into overall updates | Starting next quarter (Q3 FY25) |
| One-time transaction costs | All taken in Q3 and called out separately | Q3 FY25 |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | ₹389.4 cr, +33.4% YoY |
| EBITDA | ₹31.6 cr, +34.4% YoY |
| EBITDA margin | 8.1%, flattish YoY |
| PAT | ₹15.5 cr, +5.5% YoY |
| PAT margin | 4%, lower YoY due to higher finance costs |
| H1 FY25 revenue growth | 27.2% YoY |
| H1 FY25 EBITDA growth | 18.6% YoY |
| H1 FY25 PAT growth | 31% YoY |
| FY25 EBITDA margin outlook | flat YoY (FY24 full-year EBITDA was 9.2%); H1 FY25 EBITDA margin was 8.5% |
| Order backlog | ₹1,979 cr, down ₹147.7 cr QoQ |
| Order backlog mix | 60% export, 40% domestic |
| DIO | 122 days, improved from 184 days in Q1 |
| DSO | 82 days, improved from 92 days in Q1 |
| Customer advances | 20 days, decline due to change in business mix |
| New logos added | 2, a defense contract in India and a global oil services company |
| Altek acquisition upfront payment | $23.4 mn; earn-out capped at $5.85 mn; total max payout $29.2 mn |
| Altek financial profile | double-digit EBITDA, ROC >15%, EPS-accretive from FY26 |
| Altek industry mix | >95% industrial and medical |
| Short-term borrowings | ₹225 cr, up from ₹58 cr; borrowing for acquisition ~$12 mn (~₹100 cr) |